Individualized prevention of proton pump inhibitor related adverse events by risk stratification
Proton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their safety profile and risk stratification for high-burden diseases need further investigation. Analyzing over 2 million participants from five prospective cohorts from the US, the UK, and China, we found that...
Main Authors: | Xia, B, He, Q, Smith, FG, Gkoutos, VG, Nirantharakumar, K, Kuo, ZC, Wang, D, Feng, Q, Cheung, EC, Dai, L, Huang, J, Yu, Y, Meng, W, Qin, X, Yuan, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Nature Research
2024
|
Similar Items
-
Adverse Effects of Proton Pump Inhibitors—Evidence and Plausibility
by: Reidar Fossmark, et al.
Published: (2019-10-01) -
Impact of proton pump inhibitors on the onset of gastrointestinal immune‐related adverse events during immunotherapy
by: Angioletta Lasagna, et al.
Published: (2023-10-01) -
Adverse Drug Reactions of Proton Pump Inhibitors: A Review
by: Mohamed E.M. Mohamed, et al.
Published: (2023-06-01) -
Proton-pump inhibitors
by: Vasudevan G. Naidoo
Published: (2015-05-01) -
The effects of proton pump inhibitors on the development of post-stenting major adverse cardiovascular events in patients with acute coronary syndrome
by: Yigit Oguz Unal, et al.
Published: (2023-06-01)